Physician profile
Christopher L Carmichael
NPI 1992148340
$2,494.71
in general payments reported to CMS, 2019-2025
27 companies · $1,147 in 2025
The $1,147 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $466 · 2020: $127 · 2021: $17.85 · 2022: $17.41 · 2023: $55.56 · 2024: $665 · 2025: $1,147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,867.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,866.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $471.62 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $444.85 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $229.20 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Exact Sciences Corporation | $199.54 | 2024-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $136.79 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Phathom Pharmaceuticals, INC. | $131.91 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $105.79 | 2025 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $83.30 | 2021-2024 | Eliquis |
| Abbott Laboratories | $75.92 | 2022-2025 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $75.21 | 2019-2020 | |
| Lilly USA, LLC | $73.35 | 2019-2024 | Mounjaro, Zepbound |
| Astellas Pharma US INC | $66.84 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.76 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $56.19 | 2019-2020 | |
| Allergan, INC. | $30.64 | 2019-2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $29.86 | 2019 | |
| Corcept Therapeutics | $29.20 | 2025 | Korlym |
| Janssen Pharmaceuticals, INC | $25.49 | 2019 | |
| Inspire Medical Systems, INC. | $24.45 | 2025 | Inspire |
| Daiichi Sankyo INC. | $23.32 | 2024 | Injectafer |
| Mylan Specialty L.P. | $22.38 | 2024 | Yupelri |
| Dexcom, INC. | $19.53 | 2023 | Dexcom G6 Transmitter |
| Dynavax Technologies Corporation | $18.82 | 2025 | Heplisav-B |
| Viatris Specialty LLC | $17.35 | 2025 | Yupelri |
| Kowa Pharmaceuticals America, INC. | $15.44 | 2025 | Zoryve |
| Pfizer INC. | $13.97 | 2024 | |
| Cvrx, INC. | $10.99 | 2025 | Barostim Neo System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Carmichael listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.